The potential inhibitory effect of antiparasitic drugs and natural products on P-glycoprotein mediated efflux.

[1]  A. Ungell,et al.  Variability in mRNA expression of ABC- and SLC-transporters in human intestinal cells: comparison between human segments and Caco-2 cells. , 2006, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[2]  D. Clarke,et al.  Do drug substrates enter the common drug-binding pocket of P-glycoprotein through "gates"? , 2005, Biochemical and biophysical research communications.

[3]  O. Razum,et al.  Community effectiveness of chloroquine and traditional remedies in the treatment of young children with falciparum malaria in rural Burkina Faso , 2004, Malaria Journal.

[4]  W. Gaus,et al.  Pharmacokinetic Herb-Drug Interactions: Are Preventive Screenings Necessary and Appropriate? , 2004, Planta medica.

[5]  A. Ungell,et al.  Cell Cultures in Drug Discovery: An Industrial Perspective , 2004 .

[6]  P. Sinko,et al.  Intestinal drug transporters: in vivo function and clinical importance. , 2004, Current drug metabolism.

[7]  K. Wen,et al.  Lethal quercetin-digoxin interaction in pigs. , 2004, Life sciences.

[8]  G. Dresser,et al.  The effects of fruit juices on drug disposition: a new model for drug interactions , 2003, European journal of clinical investigation.

[9]  A. Fairlamb.  Chemotherapy of human African trypanosomiasis: current and future prospects. , 2003, Trends in parasitology.

[10]  Chava Kimchi-Sarfaty,et al.  P-glycoprotein: from genomics to mechanism , 2003, Oncogene.

[11]  Ismael Zamora,et al.  pH-Dependent Bidirectional Transport of Weakly Basic Drugs Across Caco-2 Monolayers: Implications for Drug–Drug Interactions , 2003, Pharmaceutical Research.

[12]  Han van de Waterbeemd,et al.  Drug bioavailability : estimation of solubility, permeability, absorption and bioavailability , 2003 .

[13]  H. Glaeser,et al.  P‐glycoprotein‐mediated intestinal and biliary digoxin transport in humans , 2003, Clinical pharmacology and therapeutics.

[14]  P. Augustijns,et al.  Apricot extract inhibits the P-gp-mediated efflux of talinolol. , 2002, Journal of pharmaceutical sciences.

[15]  H. Mousa,et al.  Effect Of Grapefruit Juice On Plasma Chloroquine Kinetics In Mice , 2002, Clinical and experimental pharmacology & physiology.

[16]  Ming Hu,et al.  Absorption and metabolism of flavonoids in the caco-2 cell culture model and a perused rat intestinal model. , 2002, Drug metabolism and disposition: the biological fate of chemicals.

[17]  A. Mitchell,et al.  Recent patterns of medication use in the ambulatory adult population of the United States: the Slone survey. , 2002, JAMA.

[18]  H. Melhus,et al.  Correlation of gene expression of ten drug efflux proteins of the ATP-binding cassette transporter family in normal human jejunum and in human intestinal epithelial Caco-2 cell monolayers. , 2001, The Journal of pharmacology and experimental therapeutics.

[19]  R. Borchardt,et al.  A Functional Assay for Quantitation of the Apparent Affinities of Ligands of P-Glycoprotein in Caco-2 Cells , 2001, Pharmaceutical Research.

[20]  P. Morgan,et al.  Role of transport proteins in drug absorption, distribution and excretion , 2001, Xenobiotica; the fate of foreign compounds in biological systems.

[21]  C. Wandel,et al.  Increased drug delivery to the brain by P‐glycoprotein inhibition , 2000, Clinical pharmacology and therapeutics.

[22]  G. Williamson,et al.  Dietary intake and bioavailability of polyphenols. , 2000, The Journal of nutrition.

[23]  M Zschiesche,et al.  Oral bioavailability of digoxin is enhanced by talinolol: Evidence for involvement of intestinal P‐glycoprotein , 2000, Clinical pharmacology and therapeutics.

[24]  H. Kotaki,et al.  Quantitative prediction of metabolic inhibition of midazolam by erythromycin, diltiazem, and verapamil in rats: implication of concentrative uptake of inhibitors into liver. , 2000, The Journal of pharmacology and experimental therapeutics.

[25]  M. Klepser,et al.  Assessment of Patients' Perceptions and Beliefs Regarding Herbal Therapies , 2000, Pharmacotherapy.

[26]  E. Buxbaum.  Co-operative binding sites for transported substrates in the multiple drug resistance transporter Mdr1. , 1999, European journal of biochemistry.

[27]  R. Oertel,et al.  Intestinal secretion of intravenous talinolol is inhibited by luminal R‐verapamil , 1999, Clinical pharmacology and therapeutics.

[28]  A. Das,et al.  Diospyrin, a bisnaphthoquinone: a novel inhibitor of type I DNA topoisomerase of Leishmania donovani. , 1998, Molecular pharmacology.

[29]  A. di Pietro,et al.  Flavonoids: a class of modulators with bifunctional interactions at vicinal ATP- and steroid-binding sites on mouse P-glycoprotein. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[30]  M. Foley,et al.  Quinoline antimalarials: mechanisms of action and resistance and prospects for new agents. , 1998, Pharmacology & therapeutics.

[31]  R. Walgren,et al.  Transport of quercetin and its glucosides across human intestinal epithelial Caco-2 cells. , 1998, Biochemical pharmacology.

[32]  K. Paull,et al.  P-glycoprotein substrates and antagonists cluster into two distinct groups. , 1997, Molecular pharmacology.

[33]  B. Hirst,et al.  Intestinal secretion of drugs. The role of P-glycoprotein and related drug efflux systems in limiting oral drug absorption , 1997 .

[34]  A. F. Castro,et al.  Inhibition of drug transport by genistein in multidrug-resistant cells expressing P-glycoprotein. , 1997, Biochemical pharmacology.

[35]  P. Augustijns.  Uptake and Transport Characteristics of Chloroquine in an In‐vitro Cell Culture System of the Intestinal Mucosa, Caco‐2 , 1996, The Journal of pharmacy and pharmacology.

[36]  E. Georges,et al.  Benzimidazoles, potent anti-mitotic drugs: substrates for the P-glycoprotein transporter in multidrug-resistant cells. , 1994, Biochemical pharmacology.

[37]  Babiker M. Mahmoud,et al.  Significant reduction in chloroquine bioavailability following coadministration with the Sudanese beverages Aradaib, Karkadi and Lemon. , 1994, The Journal of antimicrobial chemotherapy.

[38]  C. Masimirembwa,et al.  The effect of chloroquine on the pharmacokinetics and metabolism of praziquantel in rats and in humans , 1994, Biopharmaceutics & drug disposition.

[39]  P. Chrétien,et al.  Pharmacokinetic and pharmacodynamic study of amodiaquine and its two metabolites after a single oral dose in human volunteers. , 1993, Arzneimittel-Forschung.

[40]  N. White,et al.  A comparison of the pharmacokinetic and pharmacodynamic properties of quinine and quinidine in healthy Thai males. , 1993, British journal of clinical pharmacology.

[41]  P. Artursson,et al.  Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (Caco-2) cells. , 1991, Biochemical and biophysical research communications.

[42]  G. Alván,et al.  The disposition of chloroquine in healthy Nigerians after single intravenous and oral doses. , 1987, British journal of clinical pharmacology.

[43]  B. Hazra,et al.  Biological activity of diospyrin towards Ehrlich ascites carcinoma in Swiss A mice. , 1984, Planta medica.

[44]  B. Beermann,et al.  Disposition of chloroquine in man after single intravenous and oral doses. , 1983, British journal of clinical pharmacology.

[45]  D. Perrier,et al.  Digoxin-quinidine interaction. , 1979, Annals of internal medicine.

[46]  Christos Reppas,et al.  Dissolution Testing as a Prognostic Tool for Oral Drug Absorption: Immediate Release Dosage Forms , 2004, Pharmaceutical Research.

[47]  A. Dahan,et al.  Food–drug interaction: grapefruit juice augments drug bioavailability—mechanism, extent and relevance , 2004, European Journal of Clinical Nutrition.

[48]  C. Rumi,et al.  Quercetin potentiates the effect of adriamycin in a multidrug-resistant MCF-7 human breast-cancer cell line: P-glycoprotein as a possible target , 2004, Cancer Chemotherapy and Pharmacology.

[49]  P. C. M. Pereira.  Interaction between infection, nutrition and immunity in tropical medicine , 2003 .

[50]  G. Jang,et al.  Dietary Effects on Drug Metabolism and Transport , 2003, Clinical pharmacokinetics.

[51]  P. J. Vries,et al.  Pharmacokinetic Interactions of Antimalarial Agents , 2001, Clinical pharmacokinetics.

[52]  J Ferté,et al.  Analysis of the tangled relationships between P-glycoprotein-mediated multidrug resistance and the lipid phase of the cell membrane. , 2000, European journal of biochemistry.

[53]  I. Pastan,et al.  Biochemical, cellular, and pharmacological aspects of the multidrug transporter. , 1999, Annual review of pharmacology and toxicology.

[54]  B. Abegaz,et al.  Geshoidin: A bitter principle of Rhamnus prinoides and other constituents of the leaves , 1995 .

[55]  A. Breckenridge,et al.  The disposition of amodiaquine in man after oral administration. , 1987, British journal of clinical pharmacology.